by Madaline Spencer | May 30, 2024
The U.S. Food and Drug Administration (FDA) has approved Bkemv (eculizumab-aeeb), an interchangeable biosimilar to Soliris (eculizumab). The treatment is approved for both paroxysmal nocturnal hemoglobinuria (PNH), to reduce hemolysis, and atypical hemolytic uremic...
by Madaline Spencer | May 29, 2024
Amanda Cali, Co-founder of Tin Soldiers Global, discusses how the organization helps find patients with fibrodysplasia ossificans progressiva (FOP) and other rare diseases. FOP is a rare disorder in which skeletal muscle and connective tissue are...
by Madaline Spencer | May 27, 2024
Michael Snape, PhD, Chief Science Officer at AMO Pharma, discusses the efficacy of AMO-02 (tideglusib) for myotonic dystrophy type 1 (DM1). DM1 is a genetic disease affecting the muscles and other body systems. Three forms of DM1 may present: the mild...
by Madaline Spencer | May 23, 2024
Karen Anderson, MD, neuropsychiatrist at Georgetown University, Director of Huntington’s Disease Care, Education, and Research Center, discusses Austedo (deutetrabenazine) to treat patients with Huntington’s disease (HD). HD is a progressive disorder...
by Madaline Spencer | May 21, 2024
Alan Percy, MD, pediatric neurologist at University of Alabama at Birmingham, discusses the DAFFODIL clinical trial, testing the safety and tolerability of trofinetide for the treatment of Rett syndrome. Rett syndrome is a neurodevelopmental condition...
